NCT04683965View on ClinicalTrials.gov

Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2024

Study Completion Date

May 1, 2024

Conditions
Colorectal Neoplasms
Interventions
DRUG

Pemetrexed

Pemetrexed 500 mg/m2 d1

DRUG

TAS-102

TAS-102, capsule, 35mg/m2, bid,p.o, d1\~5,d8\~12

DRUG

Bevacizumab

Bevacizumab 5 mg/kg d1,d14

Trial Locations (1)

210029

the First Affiliated Hospital of Nanjing Medical University, Nanjing

Sponsors
All Listed Sponsors
collaborator

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT04683965 - Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer | Biotech Hunter | Biotech Hunter